GPR40 agonist was reported to improve cognition and reduce β-amyloid formation in a mouse model of Alzheimer’s disease (Chen et al., 2021; Liu et al., 2021). Here, FFAR1 is linked to early-onset autosomal dominant Alzheimer disease.